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Abstract
Background: Laryngopharyngeal reflux (LPR) is the backflow of stomach contents into the throat. The
current standard of care is to treat patients with a proton pump inhibitor (PPI) twice daily for up to 6 months
or longer. Two meta-analyses were completed in 2006 and found no evidence PPI therapy is better than
placebo for chronic laryngitis. Since that time new tools have been created to measure outcomes in this field of
research, the Reflux Finding Score (RFS) and Reflux Symptom Index (RSI). Using these standardized
measures are researchers able to demonstrate PPI therapy is efficacious in the treatment of LPR?
Method: An exhaustive literature search using the Medline, EBMRM, and CINAHL search engines was
conducted from 2006-present with the following search terms: laryngopharyngeal reflux, proton pump
inhibitors, extraesophageal, laryngitis, globus, throat clearing, and chronic cough. Randomized controlled
trials comparing PPI to placebo for the treatment of laryngopharyngeal reflux in adults were included. Trials
were excluded if completed before 2006 or if they were previously evaluated in a meta-analysis. Studies were
evaluated for quality using the GRADE criteria. Results: Three studies met inclusion criteria and were
evaluated in this systematic review. A double-blind, randomized, placebo-controlled trial with 82 participants
demonstrated a statistically significant reduction in the total RSI scores after 12 weeks of treatment, this effect
disappeared once treatment was stopped. Another double-blind, randomized, placebo-controlled trial with 41
participants found no difference from baseline in any of their outcome measures. Finally a double-blind,
randomized, placebo-controlled trial found statistically significant reduced RSI at week 12. This was the only
study able to demonstrate improvement in the RFS after 12 weeks of treatment.
Conclusion: The use of proton pump inhibitors for LPR continues to be a topic surrounded with controversy.
Current research supports a trial of twice daily PPI for at least 3 months if the patient is also experiencing
symptoms of GERD. Patients with throat symptoms alone are unlikely to find relief from PPI therapy and
should be evaluated for other possible etiologies. The purpose of this review is to evaluate the latest placebo
controlled RCT using the RFS1and RSI2to evaluate the efficacy of PPI therapy for LPR.
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ABSTRACT 
Background: Laryngopharyngeal reflux (LPR) is the backflow of stomach contents into 
the throat. The current standard of care is to treat patients with a proton pump inhibitor 
(PPI) twice daily for up to 6 months or longer. Two meta-analyses were completed in 
2006 and found no evidence PPI therapy is better than placebo for chronic laryngitis. 
Since that time new tools have been created to measure outcomes in this field of research, 
the Reflux Finding Score (RFS) and Reflux Symptom Index (RSI). Using these 
standardized measures are researchers able to demonstrate PPI therapy is efficacious in 
the treatment of LPR? 
 
Method: An exhaustive literature search using the Medline, EBMRM, and CINAHL 
search engines was conducted from 2006-present with the following search terms: 
laryngopharyngeal reflux, proton pump inhibitors, extraesophageal, laryngitis, globus, 
throat clearing, and chronic cough.  Randomized controlled trials comparing PPI to 
placebo for the treatment of laryngopharyngeal reflux in adults were included. Trials 
were excluded if completed before 2006 or if they were previously evaluated in a meta-
analysis.  Studies were evaluated for quality using the GRADE criteria. 
 
Results: Three studies met inclusion criteria and were evaluated in this systematic 
review. A double-blind, randomized, placebo-controlled trial with 82 participants 
demonstrated a statistically significant reduction in the total RSI scores after 12 weeks of 
treatment, this effect disappeared once treatment was stopped. Another double-blind, 
randomized, placebo-controlled trial with 41 participants found no difference from 
baseline in any of their outcome measures. Finally a double-blind, randomized, placebo-
controlled trial found statistically significant reduced RSI at week 12. This was the only 
study able to demonstrate improvement in the RFS after 12 weeks of treatment. 
 
Conclusion: The use of proton pump inhibitors for LPR continues to be a topic 
surrounded with controversy. Current research supports a trial of twice daily PPI for at 
least 3 months if the patient is also experiencing symptoms of GERD. Patients with throat 
symptoms alone are unlikely to find relief from PPI therapy and should be evaluated for 
other possible etiologies. The purpose of this review is to evaluate the latest placebo 
controlled RCT using the RFS1and RSI2to evaluate the efficacy of PPI therapy for LPR. 
 
Keywords: Laryngopharyngeal reflux, proton pump inhibitor, Reflux Symptom Index, 
Reflux Finding Score 
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The Efficacy of Proton Pump Inhibitor Therapy for the Treatment of 
Laryngopharyngeal Reflux: A Systematic Review 
BACKGROUND 
 Laryngopharyngeal reflux (LPR) is the backflow of stomach contents into the 
throat. It is commonly identified in otolaryngologist offices and diagnosed in almost 10% 
of their patient population. 1 Additionally, 50% of patients with voice disorders may have 
LPR. 2 Other terms used to describe this condition include: posterior laryngitis, 
extraesophageal reflux, reflux laryngitis, or supraesophageal reflux. Most clinicians are 
more familiar with gastroesophageal reflux disease (GERD), the backflow of stomach 
contents into the esophagus, which typically results in heartburn and regurgitation.  
Patients with LPR and GERD differ in many ways. The majority of patients with LPR do 
not experience the characteristic heartburn of GERD; they tend to reflux during the day 
while upright versus at night while lying flat; and dysfunction is believed to originate in 
the upper esophageal sphincter versus the lower esophageal sphincter. 3  
 The larynx does not have the protective mechanisms of the esophagus to defend 
against acid exposure leading to irritation of the laryngeal mucosa and subsequent 
symptoms of chronic cough, hoarseness, dysphagia, globus (sensation of lump in the 
throat), frequent throat clearing and throat discomfort. 2,3 Making an accurate diagnosis 
can be difficult, as these same symptoms can be attributed to allergies, environmental 
triggers, smoking, and vocal abuse. 2,4 If left untreated LPR can lead to severe 
complications such as contact ulcers, granulomas and stenosis. 2 Some researchers are 
connecting LPR with increased incidence of adenocarcinoma of the larynx.5,6 
 The position statement of the American Academy of Otolaryngology-Head and 
Neck Surgery7 on LPR states that a diagnosis can be made based on a correlation between 
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clinical symptoms of the disease and laryngeal findings on endoscopy.  Signs specific for 
LPR include true/false vocal fold erythema/edema; posterior cricoid wall erythema; 
posterior commissure erythema/edema; and posterior pharyngeal wall erythema/edema.  8 
Often clinically no testing is undertaken and patients suspected of having LPR are treated 
empirically with proton pump inhibitor therapy and resolution of their symptoms is 
considered diagnostic. 9 Despite its lack of sensitivity and specificity for LPR the gold 
standard for diagnosis is 24-hour double probe pH monitoring with the upper probe 
positioned in the hypopharynx. 8,10 This test can be performed if a patient is refractory to 
proton pump inhibitor (PPI) treatment. 8,11   
 The treatment of LPR, recommended by otolaryngologists, advocates for lifestyle 
modification along with the initiation of PPI twice daily for a minimum of 6 months.  3 
The lack of randomized controlled trials supporting this treatment makes it controversial.  
12,13
 The twice daily dosing is necessary because PPIs are unable to suppress acid for 
greater than 16.8 hours. 14 Symptoms improve within 2-3 months but the laryngeal injury 
caused by the acid exposure requires prolonged treatment. 15 Lifestyle modifications 
include: elevating the head of bed 6 inches, smoking cessation, low fat diet, weight loss, 
avoid lying down within 3 hours of eating, small frequent meals, bicarbonate gum 
chewing, preferential sleeping on the left side, and avoidance of refluxogenic foods. 16 
Finally, if patients have failed all avenues of treatment and symptoms are severe, 
laparoscopic fundoplication surgery may be warranted.17 
 The American Gastroenterological Association4 reported poor sensitivity and 
specificity of endoscopy and pH monitoring for LPR results in over diagnosis and over 
treatment of the condition.  Furthermore, they recommend PPI therapy should only be 
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utilized if the patient is also experiencing symptoms of GERD, and it should not exceed a 
treatment period of 2 months. They therefore dispute the efficacy of using PPI therapy for 
patients with symptoms of LPR alone. 4,18 Finally they site the lack of randomized 
controlled trials supporting PPI therapy for LPR.  4,12,13  
 Belfasky et al2,15 created the Reflux Finding Score (RFS) and Reflux Symptom 
Index (RSI) to standardize both the laryngeal findings and symptoms of acid reflux in 
patients so outcomes in this area of research could be more accurately measured. The 
RFS is a severity scale with 8 items: subglottic edema; ventricular obliteration; 
erythema/hyperemia; vocal fold edema; diffuse laryngeal edema; posterior commissure 
hypertrophy; granuloma/granulation tissue; and thick endolaryngeal mucus. The possible 
score ranges from a minimum of 0 to a maximum of 26. A score of greater than 7 is 95% 
sensitive for LPR. The RSI is a self-administered 9-item severity scale for symptoms of 
LPR. Patients rank each of the nine symptoms on a scale from 0 to 5, 0 being “no 
problem” and 5 being a “severe problem”.  The symptoms assessed include: hoarseness, 
throat clearing, post-nasal drip, dysphagia, breathing difficulties, chronic cough, lump in 
the throat, and heartburn.  A score of greater than 13 is considered abnormal.   
 Two meta-analyses were completed in 2006 demonstrating that PPI therapy for 
LPR was no better than placebo.  12,13 Qadeer et al12 evaluated data from 8 randomized 
controlled trials (RCTs) using either a primary outcome of 50% or greater reduction in 
LPR symptoms, or complete symptom resolution. Only one of the studies analyzed used 
a standardized tool to measure outcomes. This lack of standardization resulted in 
significant heterogeneity. 12,19 Proton pump inhibitor therapy was once thought to have a 
low side effect profile but research is emerging demonstrating that it can lead to 
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infectious complications and nutritional deficiencies. 20 It is imperative that clinicians 
determine the appropriate dosage and length of treatment required for LPR. The purpose 
of this review is to evaluate the latest placebo controlled RCT using the RFS and RSI to 
evaluate the efficacy of PPI therapy for LPR. 
METHODS 
 An exhaustive literature search using the Medline, EBMRM, and CINAHL search 
engines was conducted from 2006-present with the following search terms: 
laryngopharyngeal reflux, proton pump inhibitors, extraesophageal, laryngitis, globus, 
throat clearing, and chronic cough.  Randomized controlled trials comparing PPI to 
placebo for the treatment of LPR in adults were included. Trials were excluded if 
completed before 2006, or if they were previously evaluated in a meta-analysis.  Studies 
written in foreign language and not translated were also excluded. Relevant articles were 
assessed for quality using the Grading of Recommendations, Assessment, Development 
and Evaluation (GRADE) 21.  
RESULTS 
 A systematic literature review resulted in 102 potential articles for consideration. 
Five additional articles were obtained from the bibliography of UpToDate on the topic of 
LPR22. After duplicates were removed 82 remained. Seventy-five were excluded based 
on review of title or abstract. There were 7 full text articles assessed for eligibility of 
which 4 were excluded because they did not use a control group for comparison, or 
measured an outcome other than LPR symptoms such as the amount of pepsin in the 
sputum. The remaining 3 articles met all inclusion and exclusion criteria (Table 1). 19,23,24  
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Lam et al 2010 
 This prospective, double-blind, randomized, placebo controlled study19 was 
conducted in China. A total of 82 participants were enrolled but only 40 were analyzed in 
each arm. The average age was 46.86 and 28% were male. The patients were gathered 
from an outpatient otolaryngologist office and diagnosed with LPR via videostroboscopy. 
Participants were included if they met the following criteria; the presence of at least 1 of 
the following: hoarseness, globus, throat discomfort, and throat clearing for at least 1 
month in the preceding 1 year; and endoscopic evidence of LPR with a RFS > 7 and 
absence of upper respiratory infection in the past 4 weeks or allergic causes of laryngitis. 
Participants were excluded if they were younger than 18, had an identifiable laryngeal 
pathology other than LPR, a history radiotherapy, gastroesophageal surgery, or if they 
were on acid suppressive therapy within the previous 4 weeks. Patients were randomized 
in a 1:1 fashion using computer-generated random numbers. The treatment group 
received rabeprazole 20mg twice daily for 12 weeks and implemented lifestyle 
modifications. Outcomes were measured using the RFS and RSI. There was no 
statistically significant difference in RFS between the treatment and placebo groups. 
There was statistically significant improvement between the treatment and placebo 
groups RSI at week 6 and week 12. This effect could no longer be demonstrated at week 
18, which was 6 weeks after discontinuing the treatment. The authors conclude that 
patients with LPR require longer treatment duration with PPI. The funding for this 
research was provided by EISAI Company Limited the developers of rabeprazole. 
Fass et al 2009 
 This prospective, double-blind, randomized, placebo controlled study23 was 
conducted in the United States. There were a total 41 participants and all were analyzed 
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as part of the data. Twenty-four patients were allocated to the treatment group and 17 to 
the placebo group. The average age was 63.25 and 58% were male. The patients were 
gathered from an outpatient otolaryngology clinic and diagnosed with LPR via 
videostroboscopy. Participants were included in the study if they met any of the 
following criteria, had posterior laryngitis in combination with: hoarseness, cough, throat 
clearing, throat discomfort and globus; and GERD related laryngeal mucosal changes. 
Participants were excluded if they were currently on anti-reflux treatment, had a history 
of prior reflux or esophageal surgery, had been intubated in the preceding 3 months, had 
been diagnosed with oropharyngeal or laryngeal cancer, were pregnant, or had an allergy 
to PPI. They also excluded patients with any severe comorbidities. The authors provide 
no information on how the randomization process was conducted. The treatment group 
received esomeprazole 20mg twice daily for 12 weeks combined with implementing 
lifestyle modifications. Outcomes were measured using the RFS, a daily voice use diary, 
the Laryngopharyngeal Reflux Health-Related Quality of Life Questionnaire (LPR-
HRQL), the Short Form 36 (SF-36), and acoustic voice measurements. The study found 
no statistically significant difference between the treatment group and placebo group for 
any of the outcomes measured. They also found no difference in a subgroup analysis of 
patients with abnormal esophagogastroduodenoscopy (EGD) findings at baseline. The 
study was partially funded by Astra-Zeneca the makers of esomeprazole. 
Reichel et al 2008 
 This prospective, double-blind, randomized, placebo controlled trial24 was 
conducted in Germany. A total of 62 participants were enrolled and 58 were analyzed at 
the studies completion. Thirty-one were allocated to the treatment group and 31 to the 
placebo group. The average age was 48.7 and 51% were male. The patients were 
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gathered from an outpatient otolaryngologist office and diagnosed with LPR via 
videostroboscopy. Participants were included in the study if they had a RFS of greater 
than 7 and a RSI of greater than 13.  Participants were excluded if they were younger than 
18, had a history of laryngeal malignancy or gastrointestinal surgery, or if they had the 
need for continuous anticoagulation therapy with warfarin or aspirin. They were also 
excluded if they were treated with PPI or any other anti-reflux medication within the 
previous 3 months, were pregnant or lactating, had an allergy to a PPI, had a drug or 
alcohol addiction or any psychiatric disease. Patients were randomized in a 1:1 ratio, and 
the placebo pill was identical to the esomeprazole.  The treatment group received 
esomeprazole 20mg twice daily for 12 weeks. No lifestyle modifications were 
implemented. Outcomes were measured using the RFS and RSI.  The treatment and 
placebo groups demonstrated statistically significant improvement in the total RFS and 
RSI at week 6. There was no difference however, when the treatment group was 
compared to the placebo group. At 12 weeks the RSI of both study groups demonstrated 
improvement with a stronger effect in the treatment group. The study was funded by 
Astra-Zeneca the makers of esomeprazole. 
DISCUSSION 
 The treatment of LPR with PPI therapy continues to be a highly controversial 
topic between the fields of otolaryngology and gastroenterology. 4,5,25,26 The lack of 
adequate diagnostic testing and a proliferation of weak evidence for treatment leaves the 
practicing clinician with little guidance and their patients filled with frustration.11,25,27 
Proton pump inhibitor therapy once thought to be an extremely safe treatment option, is 
now demonstrating complications related to respiratory infections, Clostridium difficile 
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infections, and bone fractures with prolonged use.20 Two of the studies in this review 
demonstrate significant improvement in symptoms after 12 weeks of treatment.19,24 
Reichel et al24 found patients improved the most in the symptom category of heartburn. 
Lam et al19 also noted the most improvement in heartburn, chest pain, indigestion, and 
excess throat mucus. These symptoms are characteristic of patients with classic GERD. 
Therefore, it appears, that patients with LPR and concomitant GERD symptoms, will 
achieve the greatest benefit from PPI therapy.25 It is important to consider other etiologies 
such as nonacid refluxate, sinusitis, vocal abuse, allergies, or other environmental agents 
if a patient’s symptoms do not respond to an initial 3-month trial of treatment.3,25,28 
Shorter duration trials have been used to question the efficacy of PPI therapy but in the 
Reichel et al study the placebo effect that was seen at 6 weeks disappeared at 12 
weeks.24,25 This raises the question as to whether or not it is appropriate to discontinue 
PPI therapy prematurely after a trial of only 2 months.5 
 All three studies19,23,24 used the RFS to evaluate laryngeal finding outcomes.  Only 
Reichel et al24 was able to demonstrate a statistically significant improvement in 
laryngeal findings after 12 weeks of treatment when compared to placebo. They found 
the greatest improvement in posterior commissure hypertrophy (P <0.01). This is 
considered one of the most characteristic findings of LPR. 1 Lam et al19 was unable to 
demonstrate a difference in laryngeal findings at 6, 12, or 18 weeks.  When they 
compared baseline characteristics of the treatment group at 12 weeks the RFS was lower 
overall, specifically in vocal cord edema and laryngeal edema. Similar changes were 
found in the placebo group however, with decreased overall scores, and decreased vocal 
cord edema and laryngeal edema subgroup scores. Even at week 18, patients in the 
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placebo group continued to demonstrate improvement. The authors attribute lifestyle 
modifications to the ongoing decrease in RFS. The Fass et al study23 showed no 
improvement in total RFS after 12 weeks of treatment. They found no difference between 
the treatment group and the placebo group and no difference could be observed within the 
groups when compared to baseline. 
 Lam et al19 and Reichel et al24  utilized the RSI to measure symptom outcomes.  
Lam et al measured reduced total RSI scores at week 6 and 12. The most improvement 
between the groups was in breathing difficulties or choking episodes, troublesome or 
annoying cough, and globus. By week 18 a statistical difference could no longer be 
calculated. The authors believe this indicates PPI therapy for LPR requires treatment 
longer than 3 months. At 6 and 12 weeks when the treatment groups were compared to 
their baselines both studies demonstrated a statistically significant improvement in 
heartburn symptoms, but not throat symptoms. Fass et al23used two health care quality of 
life questionnaires, the LPR-HRQL and the SF-36 combined with a voice use diary, and 
evaluated acoustic voice parameters to monitor improvement in symptoms. No 
statistically significant difference could be found at baseline, 6, or 12 weeks, between the 
treatment and control groups or within either group.  
 While the studies by Fass et al,23 Lam et al,19 and Reichel et al24 all provided 
important findings in the management of LPR with PPI therapy they also had limitations. 
All the studies had a small sample size. They were funded fully or in part by 
pharmaceutical companies. Publication bias seems less likely for Fass et al23 due to the 
lack of outcomes in their study. All studies chose to use 20mg twice daily as a dosing 
schedule. The current standard of care for LPR is 40mg twice daily. 11 Reichel et al24 
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chose 20mg because the typical practice for primary care providers in Germany is to start 
patients at a low dose. Fass et al used 20mg because there is no approved indication for 
40mg PPI twice daily. The RFS1 can be subject to examiner bias; the Reichel et al study24 
did not randomize their videostroboscopic exams and used only one blinded examiner for 
all patients. Therefore only the medication aspect of the study was double-blinded.  The 
pharmaceutical company who funded the study was also involved in their randomization 
process further contributing to a publication bias. Ongoing research for LPR needs to 
have larger sample sizes, to study patients taking 40mg daily, and to follow patients for a 
minimum of 6 months. Diagnostic tests need to be refined so the inclusion criteria for 
research studies can be more objective.9,25,27 
CONCLUSION 
 The use of proton pump inhibitors for LPR continues to be a topic surrounded 
with controversy. The overall combined quality of the studies reviewed was low based on 
the GRADE criteria. 21 The research supports a trial of twice daily PPI for at least 3 
months if the patient is also experiencing symptoms of GERD. 25 Patients with throat 
symptoms alone are unlikely to find relief from PPI therapy and should be evaluated for 
other possible etiologies such as non-acid reflux, allergies, sinusitis, environmental 
triggers, smoking, and vocal abuse. 3 Until the medical community is able to develop a 
diagnostic test sensitive and specific enough to accurately detect LPR the inclusion 
criteria used in research will continue to dilute the findings. 25,27 Further RCT that mirror 
the 40mg twice daily dosage used in clinical practice are needed, along with larger 
sample sizes, longer duration of study, and funding provided by an unbiased source.  
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TABLE 1 Characteristics of Reviewed Studies, GRADE profile 
aLacked precision secondary to all data provided as P values as well as small sample sizes. 
b Fass et al23 placebo group had more males and were older than the treatment group. The placebo group also had more severe reflux symptoms and a higher # of acid reflux events and total acid exposure time than the treatment group.  
c  The RSI, LPR-HRQL, SF-36, and voice diary are all subject to recall bias. All the studies were funded fully or in part by pharmaceutical companies. Fass et al23 demonstrates less likelihood of publication bias due to the lack of positive outcomes. 
 
 
 
 
Quality Assessment Summary of Findings  
 Downgrade Criteria  Number of Patients 
Changes from baseline 
after 12 weeks 
Statistically 
Significant  
Quality Importance 
No. of 
Studies 
Design Limitations Indirectness Imprecision Inconsistency 
Publication 
bias likely 
Study 
Treatment 
(total) 
Placebo 
(total) 
Mean Differences ± 
standard error of the mean 
(P value)  
P value of 
<0.05 
 
 
REFLUX FINDING SCOR 
3 
 
3 RCT 
 
 No serious 
limitations 
No serious 
indirectness 
Serious 
imprecisiona 
Serious 
inconsistenciesb 
Bias 
unlikely 
Fass et al23 24 17 (0.40) NO Low Moderate 
Lam et al19 42  40 0.54 ± 0.69 (.017) YES Low Moderate 
Reichel et al24 30 28 2.28 ± 0.98  YES Low Moderate 
REFLUX SYMPTOM INDEX 
2 
2 RCT 
 
No serious 
limitations 
No serious 
indirectness 
Serious 
imprecisiona 
 Serious 
inconsistenciesb 
Bias likelyc 
Lam et al24 42 40 -3.73 ± 1.18 (.002) YES Low Moderate 
Reichel et al24 30 28 6.48 ± 2.34  YES Low Moderate 
LPR-HRQL 
1 
1 RCT 
 
No serious 
limitations 
No serious 
indirectness 
Serious 
imprecisiona 
No serious 
inconsistencies 
Bias likelyc Fass et al23 24 17 26 ± 15.472 NO Low Low 
SHORT FORM 36  
1 
1 RCT 
 
No serious 
limitations 
No serious 
indirectness 
Serious 
imprecisiona 
No serious 
inconsistencies 
Bias likelyc Fass et al23 24 17 All 8 domains P>0.05 NO Low Low 
Acoustic Measurements 
1 1 RCT 
No serious 
limitations 
No serious 
indirectness 
Serious 
imprecisiona 
No serious 
inconsistencies 
Bias 
unlikely 
Fass et al23 24 17 All 5 measures P>0.05 NO Low Low 
Voice Diary 
1 1 RCT 
No serious 
limitations 
No serious 
indirectness 
Serious 
imprecisiona 
No serious 
inconsistencies 
Bias likelyc Fass et al23 24 17 59.093 ± 20.81 NO Low Low 
